William C. Gruber
#166,577
Most Influential Person Now
American physician-scientist, pediatrician, business executive
William C. Gruber's AcademicInfluence.com Rankings
William C. Gruberphilosophy Degrees
Philosophy
#10044
World Rank
#13726
Historical Rank
#1821
USA Rank
Logic
#6983
World Rank
#8574
Historical Rank
#990
USA Rank
Download Badge
Philosophy
William C. Gruber's Degrees
- Bachelors Biology Princeton University
Similar Degrees You Can Earn
Why Is William C. Gruber Influential?
(Suggest an Edit or Addition)According to Wikipedia, William C. Gruber is an American physician-scientist, pediatrician, and business executive. He is the senior vice president of Pfizer vaccine clinical research and development. Life Gruber completed a bachelor's degree in mathematical sciences at Rice University. He earned a M.D. at Baylor College of Medicine where he completed a residency in pediatric and infectious disease. His college roommate was immunologist Barney S. Graham.
William C. Gruber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) (7900)
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020) (1707)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) (1069)
- Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. (2015) (918)
- The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. (1998) (913)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (2021) (727)
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (2021) (527)
- Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. (2001) (453)
- Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. (2000) (435)
- Natural history of neonatal herpes simplex virus infections in the acyclovir era. (2001) (431)
- Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. (2000) (394)
- Superior Relative Efficacy of Live Attenuated Influenza Vaccine Compared With Inactivated Influenza Vaccine in Young Children With Recurrent Respiratory Tract Infections (2006) (315)
- Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age (2021) (290)
- Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. (1997) (290)
- Comparison of the Efficacy and Safety of Live Attenuated Cold-Adapted Influenza Vaccine, Trivalent, With Trivalent Inactivated Influenza Virus Vaccine in Children and Adolescents With Asthma (2006) (279)
- Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. (2005) (271)
- Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children (2008) (254)
- Influenza virus infections in infants. (1997) (244)
- SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3 (2021) (240)
- Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. (1998) (226)
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. (2013) (207)
- Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. (2008) (203)
- Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. (2013) (190)
- Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. (2008) (190)
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. (2013) (182)
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers (2010) (179)
- Efficacy and Safety of a Live Attenuated, Cold-Adapted Influenza Vaccine, Trivalent Against Culture-Confirmed Influenza in Young Children in Asia (2007) (176)
- Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine (2010) (176)
- Safety, Efficacy, and Effectiveness of Cold-Adapted Influenza Vaccine-Trivalent Against Community-Acquired, Culture-Confirmed Influenza in Young Children Attending Day Care (2006) (168)
- Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. (2010) (149)
- Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. (2002) (146)
- The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. (2007) (143)
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. (2013) (141)
- RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study (2020) (140)
- Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers (2010) (139)
- Respiratory Syncytial Virus (RSV) Immune Globulin Intravenous Therapy for RSV Lower Respiratory Tract Infection in Infants and Young Children at High Risk for Severe RSV Infections (1997) (136)
- Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. (2014) (134)
- Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. (1997) (133)
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (2020) (126)
- Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age: A Double-blind Randomized Active-controlled Trial (2010) (125)
- Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. (1996) (122)
- Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine (2021) (122)
- Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. (1999) (122)
- Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults. (2007) (115)
- Live attenuated and inactivated influenza vaccine in school-age children. (1990) (113)
- Efficacy and Safety of 1 and 2 Doses of Live Attenuated Influenza Vaccine in Vaccine-Naive Children (2009) (112)
- A Randomized, Double-Blind Study of the Safety, Transmissibility and Phenotypic and Genotypic Stability of Cold-Adapted Influenza Virus Vaccine (2006) (110)
- Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. (2000) (104)
- The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. (2006) (99)
- Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine (2022) (95)
- Validation of an Immunodiagnostic Assay for Detection of 13 Streptococcus pneumoniae Serotype-Specific Polysaccharides in Human Urine (2012) (94)
- A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. (2011) (91)
- Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. (1996) (87)
- Group A streptococcal necrotizing fasciitis following varicella in children: case reports and review. (1995) (86)
- Comparison of Results of Detection of Rhinovirus by PCR and Viral Culture in Human Nasal Wash Specimens from Subjects with and without Clinical Symptoms of Respiratory Illness (2007) (83)
- Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. (2009) (81)
- Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. (2019) (80)
- Immunogenicity, Safety, and Tolerability of 13-Valent Pneumococcal Conjugate Vaccine Followed by 23-Valent Pneumococcal Polysaccharide Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant Aged ≥2 Years: An Open-Label Study (2015) (79)
- Safety, Tolerability, and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Adults 60 to 64 Years of Age (2020) (77)
- Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. (1997) (77)
- Linear single‐dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections (1993) (71)
- Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. (2004) (71)
- Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia (2013) (68)
- Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae. (2015) (66)
- Development and clinical evaluation of Prevnar 13, a 13‐valent pneumocococcal CRM197 conjugate vaccine (2012) (65)
- Evaluation of anatomic changes in young children with natural rotavirus infection: is intussusception biologically plausible? (2004) (65)
- Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. (1993) (65)
- Randomized, Controlled Trial of a 13-Valent Pneumococcal Conjugate Vaccine Administered Concomitantly with an Influenza Vaccine in Healthy Adults (2012) (64)
- Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. (2010) (64)
- Serum vitamin A levels in respiratory syncytial virus infection. (1994) (61)
- A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. (2015) (59)
- A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. (2016) (58)
- Neonatal meningitis due to Lactobacillus. (1983) (56)
- Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study. (2018) (56)
- Immunoglobulin Administration and Ribavirin Therapy: Efficacy in Respiratory Syncytial Virus Infection of the Cotton Rat (1987) (55)
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine. (2015) (54)
- Multicenter surveillance of Streptococcus pneumoniae isolates from middle ear and mastoid cultures in the 13-valent pneumococcal conjugate vaccine era. (2015) (54)
- Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. (1997) (53)
- Immunoprophylaxis and Immunotherapy of Respiratory Syncytial Virus–Infected Mice with Respiratory Syncytial Virus–Specific Immune Serum (1993) (52)
- Safety, tolerability, and immunogenicity of a 4-antigen Staphylococcus aureus vaccine (SA4Ag): Results from a first-in-human randomised, placebo-controlled phase 1/2 study. (2017) (52)
- Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada (2012) (52)
- Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: results of a 3-year study. (1994) (51)
- SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. (2017) (51)
- Evaluation of bivalent live attenuated influenza A vaccines in children 2 months to 3 years of age: safety, immunogenicity and dose-response. (1997) (49)
- A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial. (2012) (48)
- Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group (1996) (47)
- The 13-Valent Pneumococcal Conjugate Vaccine for Invasive Pneumococcal Disease in Alaska Native Children: Results of a Clinical Trial (2012) (46)
- LIVE ATTENUATED INFLUENZA VACCINE INDUCES CROSS-REACTIVE ANTIBODY RESPONSES IN CHILDREN AGAINST AN A/FUJIAN/411/2002-LIKE H3N2 ANTIGENIC VARIANT STRAIN (2004) (44)
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply. (2021) (42)
- Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination (2015) (42)
- Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. (1993) (42)
- A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. (2011) (41)
- Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses. (2008) (39)
- A post hoc assessment of duration of protection in CAPiTA (Community Acquired Pneumonia immunization Trial in Adults) (2014) (38)
- Safety, efficacy and effectiveness of cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine in adults and children. (2001) (38)
- Immunogenicity and Safety of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Japan (2013) (37)
- Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) (2017) (37)
- Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. (2017) (37)
- Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial (2020) (36)
- Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults (2015) (36)
- 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants (2015) (34)
- Acquisition of cytomegalovirus infection from birth to 10 years: a longitudinal serologic study. (1987) (33)
- Fiber gene and genomic origin of human adenovirus type 4. (1993) (32)
- Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. (2018) (31)
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants. (2011) (30)
- Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine (2011) (30)
- Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers. (2006) (29)
- A randomized study of fever prophylaxis and the immunogenicity of routine pediatric vaccinations. (2017) (29)
- 13‐valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6‐17 years of age with sickle cell disease previously vaccinated with 23‐valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study (2015) (28)
- Modeling pneumococcal nasopharyngeal acquisition as a function of anticapsular serum antibody concentrations after pneumococcal conjugate vaccine administration. (2016) (28)
- The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study (2018) (28)
- 13-valent Pneumococcal Conjugate Vaccine Given With Meningococcal C–Tetanus Toxoid Conjugate and Other Routine Pediatric Vaccinations: Immunogenicity and Safety (2012) (27)
- Single-dose pharmacokinetics of imipenem-cilastatin in neonates (1985) (27)
- A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young children. (2009) (27)
- Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. (2000) (27)
- A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of age. (2021) (26)
- Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. (2013) (26)
- A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands. (2019) (26)
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine. (2015) (25)
- Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1 ×, 2 ×, or 4 ×) in healthy subjects aged 70 years or older. (2011) (24)
- Topical immunoprophylaxis of respiratory syncytial virus (RSV)-challenged mice with RSV-specific immune globulin. (1995) (24)
- A Phase 2 Study Evaluating the Safety, Tolerability, and Immunogenicity of Two 3-Dose Regimens of a Clostridium difficile Vaccine in Healthy US Adults Aged 65 to 85 Years (2019) (23)
- Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. (1993) (23)
- Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine formulations with and without aluminum phosphate and comparison of the formulation of choice with 23-valent pneumococcal polysaccharide vaccine in elderly adults (2014) (22)
- Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine. (2011) (22)
- Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years (2021) (22)
- Post Hoc Analysis of a Randomized Double-Blind Trial of the Correlation of Functional and Binding Antibody Responses Elicited by 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines and Association with Nasopharyngeal Colonization (2014) (22)
- 13-valent Pneumococcal Conjugate Vaccine in Older Children and Adolescents Either Previously Immunized With or Naïve to 7-valent Pneumococcal Conjugate Vaccine (2014) (22)
- Population pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections (1996) (21)
- Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. (2016) (21)
- Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. (2022) (20)
- 595Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) (2014) (19)
- Vaccination strategies for the prevention of meningococcal disease (2018) (19)
- Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine (2022) (19)
- Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial (2021) (19)
- A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥65 years of age with different prior pneumococcal vaccination (2021) (19)
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2021) (19)
- Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine Given to Korean Children Receiving Routine Pediatric Vaccines (2012) (19)
- Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine. (2011) (18)
- A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults (2021) (17)
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. (2015) (17)
- Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. (2013) (16)
- An open-label randomized clinical trial of prophylactic paracetamol coadministered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated poliovirus, and Haemophilus influenzae type b vaccine (2013) (16)
- Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Vaccines in India (2013) (15)
- Open-Label Trial of Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Adults ≥50 Years of Age in Mexico (2014) (15)
- Immunogenicity, Safety and Tolerability of 3 Lots of 13-valent Pneumococcal Conjugate Vaccine Given With Routine Pediatric Vaccinations in the United States (2013) (15)
- A phase 3, randomized, double-blind trial comparing the safety and immunogenicity of the 7-valent and 13-valent pneumococcal conjugate vaccines, given with routine pediatric vaccinations, in healthy infants in Brazil. (2012) (15)
- The role of live influenza vaccines in children. (2002) (15)
- Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study. (2022) (14)
- PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children. (2017) (14)
- Immunogenicity of booster doses of 13-valent pneumococcal conjugate and Hib/MenC vaccines given at 12 months of age in the UK (2009) (13)
- Safety and Tolerability of Cold-Adapted Influenza Vaccine, Trivalent, in Infants Younger Than 6 Months of Age (2008) (13)
- Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years (2014) (13)
- Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections (1995) (13)
- A clinical trial examining the effect of increased total CRM(197) carrier protein dose on the antibody response to Haemophilus influenzae type b CRM(197) conjugate vaccine. (2008) (13)
- Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years (2023) (12)
- The epidemiology of respiratory infections in children* (1995) (12)
- Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial (2017) (12)
- Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States (2021) (12)
- Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain. (2013) (11)
- Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants (2017) (11)
- Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a randomized clinical trial (2018) (11)
- Evaluation of an intravenous immunoglobulin preparation for the prevention of viral infection among hospitalized low birth weight infants. (1990) (11)
- Immunogenicity of DTaP-IPV-Hib and MenC vaccines in the UK when administered with a 13-valent pneumococcal conjugate vaccine (2008) (10)
- Safety and immunogenicity of a booster dose of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults: A randomized phase 1 study. (2016) (10)
- Bronchiolitis: epidemiology, treatment, and prevention (1995) (9)
- Serotype-specific immune responses to pneumococcal conjugate vaccine among children are significantly correlated by individual: Analysis of randomized controlled trial data. (2018) (9)
- Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag) (2019) (9)
- Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease After Introduction Into Routine Pediatric Use (2020) (9)
- Safety, tolerability, and immunogenicity of a novel 4-antigen Staphylococcus aureus vaccine (SA4Ag) in healthy Japanese adults (2018) (9)
- A 2-Dose Schedule of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Given to Children with Sickle Cell Disease Previously Immunized with 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23): Results of a Phase 3 Study (2012) (9)
- Human capital gaps in vaccine development: an issue for global vaccine development and global health (2017) (8)
- Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine (2023) (8)
- Predicting pneumococcal community-acquired pneumonia in the emergency department: evaluation of clinical parameters. (2014) (8)
- Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine Compared With 7-valent Pneumococcal Conjugate Vaccine Among Healthy Infants in China (2016) (8)
- The impact of human vaccines on bacterial antimicrobial resistance. A review (2021) (8)
- Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines. (2010) (8)
- Toxic shock syndrome associated with Staphylococcus aureus enterocolitis. (1988) (8)
- Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. (2013) (8)
- Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Given With DTaP Vaccine in Healthy Infants in Japan (2015) (8)
- Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Manufactured With and Without Polysorbate 80 Given to Healthy Infants at 2, 3, 4 and 12 Months of Age (2015) (7)
- A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine (2021) (7)
- 109913-valent Pneumococcal Conjugate Vaccine Efficacy is Declining with Old Age: Results from an Exploratory Analysis of the CAPiTA Trial (2014) (7)
- Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Elderly Adults Previously Immunized with a 23-Valent Pneumococcal Polysaccharide Vaccine: An Open-Label Trial (2013) (7)
- 13-Valent pneumococcal conjugate vaccine (PCV13) in children partially immunized with 7-valent pneumococcal conjugate vaccine (PCV7): a phase 3, open-label trial. (2013) (7)
- Antibody Responses to Routine Pediatric Vaccines Administered With 13-valent Pneumococcal Conjugate Vaccine (2009) (6)
- 3. Phase 3 Pivotal Evaluation of 20-valent Pneumococcal Conjugate Vaccine (PCV20) Safety, Tolerability, and Immunologic Noninferiority in Participants 18 Years and Older (2020) (6)
- Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccinegiven as a 3-dose series with routine vaccines in healty children (2009) (6)
- 1558O COVID-19 vaccine in participants (ptcpts) with cancer: Subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine (2021) (6)
- A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults (2022) (5)
- A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States (2021) (5)
- Immunogenicity and safety of CRM₁₉₇ conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants. (2011) (5)
- 2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate (2019) (4)
- Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations (2018) (4)
- 1236. Safety and Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Healthy Infants in the United States (2020) (4)
- Carrier-Induced Hyporesponsiveness to Pneumococcal Conjugate Vaccines: Unraveling the Influence of Serotypes, Timing, and Previous Vaccine Dose (2020) (4)
- Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China. (2019) (4)
- The Safety and Efficacy of High-Dose (HD) Acyclovir (ACV) in Neonatal Herpes Simplex Virus (HSV) Infections (1999) (4)
- Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults (2019) (4)
- RESPIRATORY SYNCYTIAL VIRUS IMMUNE HUMAN GLOBULIN, (RSVIg) AS TREATMENT OF RSV LOWER RESPIRATORY TRACT INFECTIONS (LRI) IN CHILDREN. †1085 (1996) (4)
- Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age (2010) (4)
- Safety and immunogenicity of different Clostridioides (Clostridium) difficile vaccine formulations in two early phase randomized studies of healthy adults aged 50-85 years. (2021) (3)
- The HA1 of cold-adapted influenza B vaccine is not altered during replication in human vaccinees. (1995) (3)
- Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. (2023) (3)
- Vitamin A therapy for respiratory syncytial virus infection. (1997) (3)
- Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine (2021) (3)
- Pneumococcal Conjugate Vaccine-elicited Antibody Persistence and Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Children Previously Vaccinated with 4 Doses of Either 7-Valent or 13-Valent Pneumococcal Conjugate Vaccine (2014) (3)
- Viral Concentration in Upper and Lower Respiratory Secretions from Respiratory Syncytial Virus (RSV) Infected Children Treated with RSV Monoclonal Antibody (MEDI-493) † 830 (1998) (3)
- The Role of Vaccines in Combating Antimicrobial Resistance (2021) (3)
- 1106Modeling of nasopharyngeal acquisition as a function of anti-capsular serum antibody concentrations and of ethnicity after vaccination with pneumococcal conjugate vaccines (PCVs) (2014) (3)
- Safety and tolerability of 13-valent pneumococcal conjugate vaccine in healthy Chinese adults, children and infants (2015) (2)
- Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine (2021) (2)
- LATE BREAKER ABSTRACTS (2014) (2)
- Glycoconjugate Vaccines: The Clinical Journey (2018) (2)
- Validation of an Immunodiagnostic Assay for the Detection of 13 S. pneumoniae Serotype (2012) (2)
- S. aureus Colonization in Healthy Australian Adults Receiving an Investigational S. aureus 3-antigen Vaccine. (2019) (2)
- Safety, Tolerability and Immunogenicity of a Single Dose 4-Antigen or 3-Antigen Staphylococcus aureus Vaccine in Healthy Older Adults (2015) (2)
- Influenza: Current knowledge and strategies for intervention in children (1995) (2)
- LB748. Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults (2022) (2)
- [Heptavalent pneumococcal conjugate vaccine immunogenicity and safety in Japanese infants: primary and booster immunization results]. (2011) (2)
- Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2021) (2)
- A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. (2019) (2)
- vaccine in reducing nasopharyngeal colonization: a randomized double-blind trial (2013) (1)
- Correlation of Functional and Binding Antibody Responses (2014) (1)
- Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease (2022) (1)
- Immunization in Hematopoietic Cell Transplantation (2000) (1)
- 1098The Immunogenicity of PCV13 compared to PPSV23 in Immunocompetent Older Adults with Stable High Risk Conditions (2014) (1)
- A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age (2021) (1)
- Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age (2023) (1)
- Safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine coadministered with quadrivalent influenza vaccine: A phase 3 randomized trial. (2023) (1)
- Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine Coadministered with a Quadrivalent Influenza Vaccine in Adults 50 Years and Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (2015) (1)
- 1240. Persistence of Circulating Antibody Through 12 Months Following Vaccination With a 20-Valent Pneumococcal Conjugate Vaccine in Adults 60–64 Years of Age (2020) (1)
- Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. (2023) (1)
- Concomitantly With Influenza Vaccines in Healthy Adults (2012) (1)
- Author's response to reviews Title: An open-label randomized clinical trial of prophylactic paracetamol co-administered with 7-valent pneumococcal conjugate vaccine and hexavalent diphtheria toxoid, tetanus toxoid, 3-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilu (2012) (0)
- OF 13-VALENT PNEUMOCOCCAL CONJUGATE 1 VACCINE COMPARED TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE 2 GIVEN AS A 3-DOSE SERIES WITH ROUTINE VACCINES IN HEALTHY INFANTS 3 AND TODDLERS 4 (2010) (0)
- 1102Immunogenicity and Safety of a Second Administration of 13-Valent Pneumococcal Conjugate Vaccine Five Years after Initial Vaccination in Adults 50 Years and Older (2014) (0)
- Efficacy of Trivalent Live Attenuated Intranasal Influenza Vaccine against Monovalent Influenza H1N1 Challenge in Children (1999) (0)
- Mucosal Immune Response to Trivalent Live Attenuated Intranasal Influenza Vaccine in Children ♦ 815 (1998) (0)
- 1091Serotype Distribution of S. pneumoniae Community Acquired Pneumonia (CAP) in Adults in the Netherlands in the CAPiTA (Community-Acquired Pneumonia Immunization Trial In Adults) Study Period (2014) (0)
- IMMUNOGENICITY AND SAFETY OF 4 DOSES OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOLLOWED BY 1 DOSE OF 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS AGED >= 2 YEARS: AN OPEN LABEL CLINICAL TRIAL (2014) (0)
- 16. A Randomized Phase 1 Study of a Novel Pneumococcal Conjugate Vaccine in Healthy Japanese Adults in the United States (2020) (0)
- vaccinated children still carrying PCV 13 additional serotypes show similar carriage density to a control group of PCV 7-vaccinated children (2017) (0)
- 12. Randomized Studies of Two Clostridioides (Clostridium) difficile Vaccine Formulations (2020) (0)
- Plain language summary of Pfizer-BioNTech BNT162b2 vaccine protection against COVID-19 and its safety in participants 12- to 15-years-old (2023) (0)
- Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Given Concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults (2009) (0)
- Vaccine Clinical Development (2021) (0)
- Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Children 6–17 Years of Age in India: An Open-label Trial (2017) (0)
- 91. Establishing Proof of Concept for a Bivalent RSVpreF Subunit Vaccine for Maternal Immunization (2022) (0)
- Efficacy of a 4-Antigen Staphylococcus aureus Vaccine in Spinal Surgery: The STRIVE Randomized Clinical Trial. (2023) (0)
- A Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of a Four-Antigen Vaccine for Staphylococcus Aureus in Adults Prior to Open Posterior Spinal Fusion Surgery (2017) (0)
- Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences: 356 (1416) (2001) (0)
- Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5- to 11-Year Olds (2023) (0)
- SAFETY AND IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE 1 VACCINE COMPARED TO 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE 2 GIVEN AS A 3-DOSE SERIES WITH ROUTINE VACCINES IN HEALTHY INFANTS (2010) (0)
- Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older (2022) (0)
- 2781. Statistical Modeling to Predict Maternal RSV Vaccine Efficacy from Neutralizing Titers (2019) (0)
- 2134. A Phase 2 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Booster Dose of a Group B Streptococcus 6-Valent Polysaccharide Conjugate Vaccine (GBS6) (2022) (0)
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) (0)
- Reply to: Vitamin A for varicella (1994) (0)
This paper list is powered by the following services:
Other Resources About William C. Gruber
What Schools Are Affiliated With William C. Gruber?
William C. Gruber is affiliated with the following schools:
